Today, 30 years later, thanks to the work of the global community, we have transformed HIV into a manageable condition that’s treatable with one pill, once a day. Living a long, healthy life with HIV was once a dream but now is a reality for millions.
Stopping HIV requires constant innovation and global collaboration. Some of the world’s best scientists and most engaged health advocates are involved in advancing HIV prevention. Janssen is united with them to find a preventive vaccine and help bring a stop to HIV.
Vaccination is widely recognized as the world’s most successful and cost-effective health intervention. Today there are more than 30 infectious diseases that are vaccine-preventable. Our dream is that HIV will be one of the next, and we will work tirelessly to achieve it.
At Johnson & Johnson we are determined to combine heart, science and ingenuity to do more for people living with HIV. For the past 10 years we have been working to develop an HIV vaccine that could put an end to the pandemic for good. You have my promise that all of us at Johnson & Johnson will not rest until we defeat HIV. Together, we will make HIV history.
While controlling HIV is paramount, today the development of anti-HIV drugs also focuses on improving the lives of patients. Single-tablet regimens simplify dosing regimens and have the potential to support patient adherence and, ultimately, the effectiveness of treatment.
Janssen’s continuing commitment to advance the therapeutic options for people with HIV will benefit patients around the world, but we’re not losing sight of our ultimate goal—to find a cure. We don’t want people with HIV to have to take lifelong therapy, and we continue to explore approaches that have the potential to provide long-term remission from the infection, or full viral eradication.
We partner with many organizations across the globe to provide effective prevention and care programs for people living with HIV and at-risk populations. Working together, we are proud to expand access to vital HIV services in affected communities.
Scientists discover the virus that causes AIDS.
The first International AIDS Conference (IAC) takes place.
The World Health Organization declared December 1 to be World AIDS Day.
The U.S. Centers for Disease Control and Prevention (CDC) issues the first national treatment guidelines for the use of ARV therapy in adults and adolescents.
Approximately 3.5 million new infections occur in sub-Saharan Africa.
In 2006, Johnson and Johnson launched the Global Access and Partnerships Program, a global HIV drug access program.
Janssen’s novel protease inhibitor is approved in the U.S.
Janssen’s non-nucleoside reverse transcriptase inhibitor (NNRTI) is approved in the E.U. and U.S.
WHO estimates 5.2 million people receiving treatment for HIV.
Janssen and IAVI enter into an agreement to develop a preventive HIV vaccine based on Janssen's AdVac® adenovirus vector technology.
Janssen partners with The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and the Partnership for Supply Chain Management System (PFSCMS) to implement New Horizons Advancing Pediatric HIV Care Collaborative.
Janssen announces first-of-its kind drug donation program for HIV treatment-experienced children.
UNAIDS sets 90-90-90 goals in a bid to end the AIDS epidemic.
Agreement in 112 countries to manufacture generic versions of Janssen's NNRTI.
Janssen announces expanded collaboration with International Partnership for Microbicides for Development and Commercialization of NNRTI for prevention of sexual transmission of HIV.
Study published in Science highlights potential of investigational preventive vaccine regimen.
International Phase I/IIa clinical trial commences to evaluate safety and immunogenicity of Janssen’s HIV preventive vaccine regimen in healthy, HIV-uninfected volunteers.
Major new global commitments to end HIV infection in adolescent girls and women announced.
License granted for Janssen’s protease inhibitor to be developed and commercialized in a number of developing countries to support HIV prevention in women.
The historic challenge of finding an HIV vaccine requires global collaboration.
First efficacy study of investigational ‘global vaccine' for the prevention of HIV-1 is initiated.